Sells surgical and catheter-based heart valve replacement and repair systems to hospitals and clinicians treating cardiovascular disease.
10-K for FY2025, filed Feb 25, 2026
The company sells heart devices directly or through consignment; direct sales are completed at delivery, while consigned sales are completed when a device is implanted or used.
10-K for FY2025, filed Feb 25, 2026The Company generates nearly all of its revenue from direct product sales and sales of products under consignment arrangements. Revenue…View ↗
10-K for FY2025, filed Feb 25, 2026
FY2025 revenue by product or service ↗$6.1B
10-K for FY2025, filed Feb 25, 2026
$6.1B ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Transcatheter Aortic Valve Replacement
Sold outright
10-K for FY2025, filed Feb 25, 2026 |
74%
FY2022: 79%
|
Transcatheter Aortic Valve Replacement, FY2025
$4.5B Sources
|
Sold outright |
|
Transcatheter Mitral and Tricuspid Therapies
Sold outright
|
9.1%
FY2022: 2.6%
|
Transcatheter Mitral and Tricuspid Therapies, FY2025
$550.6M Sources
|
Sold outright |
|
Surgical Structural Heart
Sold outright
10-K for FY2025, filed Feb 25, 2026 |
17%
FY2022: 19%
|
Surgical Structural Heart, FY2025
$1B Sources
|
Sold outright |
Hospitals and clinical teams—including physicians, nurses and hospital purchasing staff—are customers. U.S. sales are mostly direct; outside the U.S., sales go through direct sales forces and independent distributors.
10-K for FY2025, filed Feb 25, 2026To achieve optimal outcomes for patients, we conduct educational symposia and best practices training for our physician, hospital…View ↗
United States. In the United States, we sell substantially all of our products through our direct sales forces. In 2025, 58% of our net…View ↗
Outside of the United States. In 2025, 42% of our net sales were derived outside of the United States through our direct sales forces and…View ↗
Yes. It kept 18 cents of every revenue dollar as net income in FY2025 and turned 22 cents into free cash flow.
10-Q for Q3 FY2026, filed Nov 4, 2026
$307.5MView ↗
10-Q for Q3 FY2026, filed Nov 4, 2026
Open tableView ↗
8-K, filed Jul 23, 2026
Increasing total company constant currency2 sales growth guidance: 10% to 11% from 9% to 11% Increasing TAVR constant currency2 sales…View ↗
8-K, filed May 4, 2026
On May 4, 2026, Edwards Lifesciences Corporation, a Delaware corporation (the “Company”), announced that Theodora Mistras has been…View ↗
Growing. Revenue grew 16% in 4 years, from $5.2B in FY2021 to $6.1B in FY2025, about 4% a year.
Exited critical care monitoring
The older report included critical-care monitoring alongside heart therapies; the latest describes structural-heart product groups and says the Critical Care business was sold.
10-K for FY2022, filed Feb 13, 2023 10-K for FY2025, filed Feb 25, 2026
Broader commercial mitral and tricuspid therapies
The older report described some transcatheter repair systems as commercially available while replacement technologies remained in development; the latest describes commercial repair and replacement therapies.
10-K for FY2022, filed Feb 13, 2023 10-K for FY2025, filed Feb 25, 2026We continue to make significant investments in the development of transcatheter heart valve repair and replacement technologies designed to…View ↗
We continue to make significant progress addressing the complex unmet needs of patients with mitral and tricuspid disease with a…View ↗
Competes with Medtronic and Abbott
10-K for FY2025, filed Feb 25, 2026We believe that we are a leading global competitor in each of our product lines. In TAVR, our primary competitors include Medtronic plc…View ↗
Loading...